Showing 5931-5940 of 9397 results for "".
- Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AKhttps://practicaldermatology.com/news/update-from-dfb-soria-on-enrollment-in-phase-2-clinical-trial-of-nanoparticle-paclitaxel-ointment-for-ak/2458039/DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, completed the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle
- Sciton and the Young Survival Coalition Partner for Breast Cancer Awarenesshttps://practicaldermatology.com/news/sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness/2458041/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- New Label Reflects Sustained Response for Sun Pharma's Odomzo in BCChttps://practicaldermatology.com/news/new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc/2458045/Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for t
- Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis/2458046/New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 mo
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C
- Lilly's Baricitinib Performs Well in Phase 2 AD Studyhttps://practicaldermatology.com/news/lillys-baricitinib-performs-well-in-phase-2-ad-study/2458052/Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatitis (AD) compared to TCS alone, with improvements seen as earl
- Vanda's Tradipitant Improves Itch and Disease Severity in AD Patientshttps://practicaldermatology.com/news/vandas-tradipitant-improves-itch-and-disease-severity-in-ad-patients/2458053/Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity, according to results from an eight-week randomized Phase 2 clinical. Tradipitant
- IPC, Others Call for Creation of Worldwide Psoriasis Databasehttps://practicaldermatology.com/news/ipc-others-call-for-creation-of-worldwide-psoriasis-database/2458055/A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report,
- Allergan Adds Coolsculpting, Other Bells and Whistles to Brilliant Distinctions® Patient Loyalty Programhttps://practicaldermatology.com/news/allergan-adds-coolsculpting-other-bells-and-whistles-to-brilliant-distinctions-patient-loyalty-program/2458056/Allergan is launching the next generation of its U.S.-based Brilliant Distinctions® program. The new offering incorporates digital innovation to enhance the consumer experience and drive increased member engagement. In addition
- FDA Approves T.R.U.E. Test Ready-To-Use Patch Test for Pediatric Usehttps://practicaldermatology.com/news/fda-approves-true-test-ready-to-use-patch-test-for-pediatric-use/2458057/The FDA has approved SmartPractice's T.R.U.E. TEST (truetest.com) ready-to-use patch test panels for pediatric patients as young as 6 years of age. T.R.U.E. TEST is the only FDA-approved product for diagnosing allergic contact derm